Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to ...
Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results